Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6194 in moderate to severe atopic dermatitis
NCT05450198Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2022
- Primary completion
- May 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
Phase 1, randomised, double-blind trial of PT101 in atopic dermatitis (AD) (6 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants Who Experience One or More Adverse Events up to 169 days and Number of Participants Who Discontinue Study Intervention Due to an AE up to 85 days. Started Aug 2022; status: completed.
02
Drugs
PT101
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05450198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05450198.